Center-Authored Papers

Filters: Author is Taplin, Mary-Ellen  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Tumor Markers, Biological
Yu EY, Duan F, Muzi M, Deng X, Chin BB, Alumkal JJ, Taplin M-E, Taub JM, Herman B, Higano CS et al..  2015.  Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 56(3):354-60. Abstract
Treatment Outcome
Yu EY, Duan F, Muzi M, Deng X, Chin BB, Alumkal JJ, Taplin M-E, Taub JM, Herman B, Higano CS et al..  2015.  Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 56(3):354-60. Abstract
Tomography, X-Ray Computed
Yu EY, Duan F, Muzi M, Deng X, Chin BB, Alumkal JJ, Taplin M-E, Taub JM, Herman B, Higano CS et al..  2015.  Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 56(3):354-60. Abstract
Thiazoles
Yu EY, Duan F, Muzi M, Deng X, Chin BB, Alumkal JJ, Taplin M-E, Taub JM, Herman B, Higano CS et al..  2015.  Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 56(3):354-60. Abstract
Survival Rate
Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PFA, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ et al..  2015.  Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. The Lancet. Oncology. 16(2):152-60. Abstract
Survival Analysis
Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S et al..  2013.  Abiraterone in metastatic prostate cancer without previous chemotherapy.. The New England journal of medicine. 368(2):138-48. Abstract
Specimen Processing Core Facility
Tamae D, Byrns M, Marck B, Mostaghel EA, Nelson PS, Lange P, Lin D, Taplin M-E, Balk S, Ellis W et al..  2013.  Development, validation and application of a stable isotope dilution liquid chromatography electrospray ionization/selected reaction monitoring/mass spectrometry (SID-LC/ESI/SRM/MS) method for quantification of keto-androgens in human serum.. The Journal of steroid biochemistry and molecular biology. 138C:281-289. Abstract
Receptors, Androgen
Yu EY, Duan F, Muzi M, Deng X, Chin BB, Alumkal JJ, Taplin M-E, Taub JM, Herman B, Higano CS et al..  2015.  Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 56(3):354-60. Abstract
Pyrimidines
Yu EY, Duan F, Muzi M, Deng X, Chin BB, Alumkal JJ, Taplin M-E, Taub JM, Herman B, Higano CS et al..  2015.  Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 56(3):354-60. Abstract
Protein Kinase Inhibitors
Yu EY, Duan F, Muzi M, Deng X, Chin BB, Alumkal JJ, Taplin M-E, Taub JM, Herman B, Higano CS et al..  2015.  Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 56(3):354-60. Abstract
Prostatic Neoplasms, Castration-Resistant
Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PFA, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ et al..  2015.  Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. The Lancet. Oncology. 16(2):152-60. Abstract
Yu EY, Duan F, Muzi M, Deng X, Chin BB, Alumkal JJ, Taplin M-E, Taub JM, Herman B, Higano CS et al..  2015.  Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 56(3):354-60. Abstract
Prostatic Neoplasms
Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S et al..  2013.  Abiraterone in metastatic prostate cancer without previous chemotherapy.. The New England journal of medicine. 368(2):138-48. Abstract
Prognosis
Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PFA, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ et al..  2015.  Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. The Lancet. Oncology. 16(2):152-60. Abstract
Prednisone
Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S et al..  2013.  Abiraterone in metastatic prostate cancer without previous chemotherapy.. The New England journal of medicine. 368(2):138-48. Abstract
Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PFA, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ et al..  2015.  Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. The Lancet. Oncology. 16(2):152-60. Abstract
Positron-Emission Tomography
Yu EY, Duan F, Muzi M, Deng X, Chin BB, Alumkal JJ, Taplin M-E, Taub JM, Herman B, Higano CS et al..  2015.  Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 56(3):354-60. Abstract
Neoplasm Staging
Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PFA, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ et al..  2015.  Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. The Lancet. Oncology. 16(2):152-60. Abstract
Neoplasm Metastasis
Yu EY, Duan F, Muzi M, Deng X, Chin BB, Alumkal JJ, Taplin M-E, Taub JM, Herman B, Higano CS et al..  2015.  Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 56(3):354-60. Abstract
Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S et al..  2013.  Abiraterone in metastatic prostate cancer without previous chemotherapy.. The New England journal of medicine. 368(2):138-48. Abstract
Middle Aged
Yu EY, Duan F, Muzi M, Deng X, Chin BB, Alumkal JJ, Taplin M-E, Taub JM, Herman B, Higano CS et al..  2015.  Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 56(3):354-60. Abstract
Male
Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S et al..  2013.  Abiraterone in metastatic prostate cancer without previous chemotherapy.. The New England journal of medicine. 368(2):138-48. Abstract
Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PFA, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ et al..  2015.  Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. The Lancet. Oncology. 16(2):152-60. Abstract
Yu EY, Duan F, Muzi M, Deng X, Chin BB, Alumkal JJ, Taplin M-E, Taub JM, Herman B, Higano CS et al..  2015.  Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 56(3):354-60. Abstract
June 2014
Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S et al..  2014.  Enzalutamide in Metastatic Prostate Cancer before Chemotherapy.. The New England journal of medicine. Abstract